Dr. Dangond is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
27 Dale Dr
Chatham, NJ 07928Phone+1 973-210-7327
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1990 - 1994
Columbia Saint Luke's Medical CenterResidency, Internal Medicine, 1988 - 1990
Pontifical Xavierian UniversityClass of 1987
Certifications & Licensure
MA State Medical License 1992 - 2025
NJ State Medical License 2007 - 2025- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 76 citationsEffects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers:Olaf Stüve, Per Soelberg Soerensen, Thomas Leist, Gavin Giovannoni, Yann Hyvert
Therapeutic Advances in Neurological Disorders. 2019-06-18 - 220 citationsSafety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.Gavin Giovannoni, Per Soelberg Sørensen, Stuart D. Cook, Kottil Rammohan, Peter Rieckmann
Multiple Sclerosis. 2018-10-01 - 86 citationsEffect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.Giancarlo Comi, Stuart D. Cook, Gavin Giovannoni, Peter Rieckmann, Per Soelberg Sørensen
Multiple Sclerosis and Related Disorders. 2019-04-01
Press Mentions
Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of SafetyJune 24th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
